Código QR (código de barras bidimensional)

Investigations of remibrutinib in models pertinent to multiple sclerosis

Inhibitors of Bruton tyrosine kinase (BTK) are actively being pursued as potential disease-modifying therapies for multiple sclerosis (MS), as attested by several completed or ongoing Phase 3 clinical trials. Yet, key aspects of BTK inhibitors biology remain unclear. Here, we assessed the effects of...

ver descrição completa

Na minha lista:
Principais autores: Rajiv W. Jain, Atefeh Rayatpour, Kathleen Hagen, Marlene T. Morch, Gurleen Randhawa, Maryam Mobarakabadi, Xiangyu Zhang, Cenxiao Li, Maryam Nakhaei-Nejad, Fabrizio Giuliani, Bruno Cenni, Mengzhou Xue, V. Wee Yong
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2026-04-01
coleção:Neurotherapeutics
Assuntos:
Multiple sclerosis
BTK inhibitor
T-bet+ memory B cells
Remibrutinib
Acesso em linha:http://www.sciencedirect.com/science/article/pii/S1878747926000930
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados